Innovative Therapeutics in Oncology and Neuroscience

Tumor Treating Fields Significant Pan-Tumor Potential in China Build On and Exceed OPTUNE GIOⓇ (GBM) • Shaping the market for TTFields • Leader in leveraging Supplemental Insurance Plans . Scalable business model • National reimbursement potential to drive 740K 5x penetration NSCLC Phase 3 45K GBM $47M annual revenue (2023) 13K Brain Metastases from NSCLC Phase 3 125K Pancreatic Cancer Phase 3 ~40x CURRENT MARKET OPPORTUNITY 410K Liver Cancer Phase 2* 480K Gastric Cancer Phase 2 26 Note: Patient numbers are China and incidence from Zai Lab market research. * Zai Lab has not participated in the study in Greater China zajǝb

View entire presentation